首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Dimethyl sulfoxide-free cryopreservation for cell therapy: A review
Institution:1. Cook Regentec, Indianapolis, IN, USA;2. Indiana University School of Medicine, Indianapolis, IN, USA;3. Process and Product Development Subcommittee, International Society for Cellular Therapy, Vancouver, BC, Canada;4. Novartis Pharmaceuticals Corporation, Morris Plains, NJ, USA;5. Charter Medical Ltd, Winston-Salem, NC, USA;6. BioLife Solutions, Bothell, WA, USA
Abstract:Cell-based therapeutics promise to transform the treatment of a wide range of diseases including cancer, genetic and degenerative disorders, or severe injuries. Many of the commercial and clinical development of cell therapy products require cryopreservation and storage of cellular starting materials, intermediates and/or final products at cryogenic temperature. Dimethyl sulfoxide (Me2SO) has been the cryoprotectant of choice in most biobanking situations due to its exceptional performance in mitigating freezing-related damages. However, there is concern over the toxicity of Me2SO and its potential side effects after administration to patients. Therefore, there has been growing demand for robust Me2SO-free cryopreservation methods that can improve product safety and maintain potency and efficacy. This article provides an overview of the recent advances in Me2SO-free cryopreservation of cells having therapeutic potentials and discusses a number of key challenges and opportunities to motivate the continued innovation of cryopreservation for cell therapy.
Keywords:Stem cell  Trehalose  Antifreeze  Hydrogel encapsulation  Vitrification
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号